More2C
ActiveFinancials · financial year 2025, abbreviated format
Annual accounts 2025 filed on 19-07-2026 at the NBB
Turnover and EBIT margin are not published. The abbreviated format does not require them. The turnover shown is an estimate from the gross margin.
Staff
| Item | 31-12-2025 |
|---|---|
| Average over the year, in full-time equivalents | 2.3 |
Source: social balance sheet in the 2025 annual accounts
Investments
| Item | 2025 |
|---|---|
| Tangible fixed assets | €40,182 |
| Financial fixed assets | €0 |
| Depreciation and write-downs of the year | €17,056 |
Source: notes to the 2025 annual accounts (statement of fixed assets)
Subsidies and aid
Flemish government
2024 to 2025 · 2 entries · €5,197 awarded · €2,697 paid| Year | Entries | Awarded | Paid |
|---|---|---|---|
| 2025 | 1 | €2,500 | €0 |
| 2024 | 1 | €2,697 | €2,697 |
Comparable companies
These companies have the same main activity as More2C: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €570,000 and €1.3m, founded between 2021 and 2022.
| Company | Founded | Total assets | Equity | Gross margin | Net result | FTE | Financial year |
|---|---|---|---|---|---|---|---|
| More2C Lievegem | 2021 | €1.0m | €0.7m | €0.3m | €0.1m | 2.3 | 2025 |
| VOX Kruisem | 2021 | €1.3m | €0.4m | €0.5m | €0.2m | 2.8 | 2025 |
| Mediso Medical Imaging Systems Belgium Oudergem | 2022 | €1.3m | -€0.1m | €0.5m | €0.1m | 2.3 | 2025 |
| Biomedico Rotselaar | 2022 | €0.7m | €0.2m | €0.4m | €0.04m | 3 | 2025 |
| HYGEMED Mons | 2022 | €0.6m | €0.3m | €0.2m | €0.1m | 1.7 | 2025 |
| Corcym Belgium Sint-Joost-ten-Node | 2021 | €1.3m | €0.5m | €0.5m | €0.02m | 3 | 2025 |
| Pharmacie Herboristerie Marie Curie Charleroi | 2022 | €0.6m | €0.09m | €0.3m | €0.02m | 3.8 | 2025 |
They were chosen from the 1,134 other active companies with that main activity and annual accounts from the past two years. All companies with this main activity
Companies with the same profile, two years later
Historical observationIn July 2024, 39,278 companies had the same profile as More2C has now. Two years later, 1.8% had gone bankrupt and 95.9% were still going.
- Micro
- 2 to 5 years old
- solvency 30% or more
- a profit of 5% of the balance sheet or more
The bankruptcy probability of More2C itself is lower: 0.1% within 12 months. It rests on far more data about More2C than the profile alone.
Test of the method
The method was tested on the 497,445 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,278 companies, not a prediction for More2C. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
| Line | 2025 |
|---|---|
| Remuneration, social security and pensions62 | €92,462 |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €17,056 |
| Provisions for liabilities and charges: additions (uses and reversals)635/8 | €10,081 |
| Other operating charges640/8 | €790 |
| Gross operating margin9900 | €279,371 |
| Operating profit (loss)9901 | €158,982 |
| Financial income75/76B | €212 |
| Recurring financial income75 | €212 |
| Financial charges65/66B | €12,437 |
| Recurring financial charges65 | €12,437 |
| Profit (loss) for the period before taxes9903 | €146,757 |
| Income taxes67/77 | €36,500 |
| Profit (loss) for the period9904 | €110,257 |
| Profit (loss) for the period to be appropriated9905 | €110,257 |
| Line | 2025 | |
|---|---|---|
| Assets | ||
| Total assets20/58 | €965,840 | |
| Fixed assets21/28 | €122,433 | |
| Intangible fixed assets21 | €39,595 | |
| Tangible fixed assets22/27 | €82,839 | |
| Plant, machinery and equipment23 | €1,091 | |
| Furniture and vehicles24 | €81,747 | |
| Current assets29/58 | €843,407 | |
| Stocks and contracts in progress3 | €111,194 | |
| Stocks30/36 | €111,194 | |
| Amounts receivable within one year40/41 | €294,461 | |
| Trade receivables40 | €294,461 | |
| Other amounts receivable41 | €0 | |
| Cash at bank and in hand54/58 | €436,248 | |
| Deferred charges and accrued income490/1 | €1,504 | |
| Equity and liabilities | ||
| Total equity and liabilities10/49 | €965,840 | |
| Equity10/15 | €657,332 | |
| Contributions10/11 | €200 | |
| Reserves13 | €657,132 | |
| Distributable reserves133 | €657,132 | |
| Profit (loss) carried forward14 | €0 | |
| Provisions and deferred taxes16 | €43,681 | |
| Provisions for liabilities and charges160/5 | €43,681 | |
| Other liabilities and charges164/5 | €43,681 | |
| Amounts payable17/49 | €264,827 | |
| Amounts payable within one year42/48 | €264,827 | |
| Trade debts44 | €79,987 | |
| Suppliers440/4 | €79,987 | |
| Taxes, remuneration and social security45 | €111,107 | |
| Taxes450/3 | €103,976 | |
| Remuneration and social security454/9 | €7,132 | |
| Other amounts payable47/48 | €73,734 | |
| Line | 2025 |
|---|---|
| Profit (loss) for the period9904 | €110,257 |
| + Depreciation and write-downs630 | €17,056 |
| Operating cash flow (approximation) | €127,313 |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Filings with the National Bank (1)
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | abbreviated format | 19-07-2026 | 2026-00310731 | NBB |